The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: Part 1-overview, detection, and staging*

Journal of Nuclear Medicine

Volumn 50, Issue 4, 2009, Pages 569-581

  Lee, Jean H ^a   Rosen, Eric L ^b   Mankoff, David A ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Seattle Radiologists   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

Breast cancer; Nuclear medicine; Oncology; PET

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FULVESTRANT; LAPATINIB; LETROZOLE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TECHNETIUM SULFUR COLLOID TC 99M; TRACER; TRASTUZUMAB;

ARTICLE; AXILLARY LYMPH NODE; BONE ATROPHY; BONE SCINTISCANNING; BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTINUING EDUCATION; DIAGNOSTIC IMAGING; DISEASE SEVERITY; HORMONAL THERAPY; HUMAN; LYMPHOSCINTIGRAPHY; MAMMOGRAPHY; METASTASIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT INDICATION; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE ENHANCEMENT; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 63849193777     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.053512     Document Type: Article

References (122)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview. Ann Oncol. 2006;17(suppl 10):x59-x62.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
4. Doyle DM, Miller KD. Development of new targeted therapies for breast cancer. Breast Cancer. 2008;15:49-56.
5. Lefferts JA, Bartels CL, Tsongalis GJ. Molecular oncology: current trends in diagnostics. Future Oncol. 2008;4:61-70.
6. Mankoff DA.Molecular imaging as a tool for translating breast cancer basic science. Breast Cancer Res. 2008;10(suppl 1):S3. Available at: breast-cancer-research.com/content/10/S1/S3. Accessed March 4, 2009.
7. Salehi F, Turner MC, Phillips KP, Wigle DT, Krewski D, Aronson KJ. Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine disruptors. J Toxicol Environ Health. 2008;11:276-300.
8. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643-646.
9. Schnitt SJ. Traditional and newer pathologic factors. J Natl Cancer Inst Monogr. 2001;2001:22-26.
10. Walker RA. Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol. 2008;61:689-696.
11. Symmans WF. A pathologist's perspective on emerging genomic tests for breast cancer. Semin Oncol. 2007;34(2, suppl 3):S4-S9.
12. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568-2581.
13. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13:477-493.
14. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56:37-47.
15. Vazquez B, Rousseau D, Hurd TC. Surgical management of breast cancer. Semin Oncol. 2007;34:234-240.
16. Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer. 1999;35:1963-1973.
17. Chen CY, Calhoun KE, Masetti R, Anderson BO. Oncoplastic breast conserving surgery: a renaissance of anatomically-based surgical technique. Minerva Chir. 2006;61:421-434.
18. Newman EA, Newman LA. Lymphatic mapping techniques and sentinel lymph node biopsy in breast cancer. Surg Clin North Am. 2007;87:353-364.
19. Gervasoni JE Jr, Sbayi S, Cady B. Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol. 2007;14:2443-2462.
20. Bellon JR, Katz A, Taghian A. Radiation therapy for breast cancer. Hematol Oncol Clin North Am. 2006;20:239-257.
21. Chen PY, Vicini FA. Partial breast irradiation: patient selection, guidelines for treatment, and current results. Front Radiat Ther Oncol. 2007;40:253-271.
22. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956-962.
23. Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw. 2006;4(suppl 1):S1-S26.
24. Come SE, Buzdar AU, Ingle JN, et al. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008;112(3, suppl):673-678.
25. Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2005;89(suppl 1):S9-S15.
26. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene. 2007;26:6577-6592.
27. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
28. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235-244.
29. Estevez LG, Martin M, Alba E, et al. Current controversies in the management of early breast cancer. Clin Transl Oncol. 2007;9:375-384.
30. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol. 2008;26:786-790.
31. Scheidhauer K, Walter C, Seemann MD. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S70-S79.
32. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA. 2005;293:1245-1256.
33. Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology. 1995;196:123-134.
34. Lehman CD, Schnall MD. Imaging in breast cancer: magnetic resonance imaging. Breast Cancer Res. 2005;7:215-219.
35. Mendelson EB. Problem-solving ultrasound. Radiol Clin North Am. 2004; 42:909-918.
36. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89.
37. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9-16.
38. 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
39. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98:267-274.
40. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27(suppl 1):S215-S229.
41. Berg WA, Weinberg IN, Narayanan D, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression (''positron emission mammography'') is highly accurate in depicting primary breast cancer. Breast J. 2006;12:309-323.
42. Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology. 2005;234:527-534.
43. Raylman RR, Majewski S, Smith MF, et al. The positron emission mammography/tomography breast imaging and biopsy system (PEM/PET): design, construction and phantom-based measurements. Phys Med Biol. 2008;53:637-653.
44. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med. 1990;31:1646-1653.
45. Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ. Uptake of Tc-99m MIBI related to tumour size and type. Anticancer Res. 1997;17:1693-1694.
46. Mankoff DA, Dunnwald LK, Gralow JR, et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol. 2002;29:719-727.
47. Scopinaro F, Schillaci O, Scarpini M, et al. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med. 1994;21:984-987.
48. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg. 1994;178:491-497.
49. Liberman M, Sampalis F, Mulder DS, Sampalis JS. Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature. Breast Cancer Res Treat. 2003;80:115-126.
50. 99mtechnetium sestamibi. Am J Surg. 2003;185:544-549.
51. 99mTc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med. 1997;27:40-54.
52. Brem RF, Fishman M, Rapelyea JA. Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. Acad Radiol. 2007;14:945-950.
53. Brem RF, Floerke AC, Rapelyea JA, Teal C, Kelly T, Mathur V. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology. 2008;247:651-657.
54. Carlson RW, Anderson BO, Burstein HJ, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2007;5:246-312.
55. Norum J, Andreassen T. Screening for metastatic disease in newly diagnosed breast cancer patients: what is cost-effective? Anticancer Res. 2000;20:2193-2196.
56. Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol. 2005;16:263-266.
57. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
58. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:1818-1822.
59. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-398.
60. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335-339.
61. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in earlystage breast cancer. J Clin Oncol. 2005;23:7703-7720.
62. Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007;245:452-461.
63. Vanderveen KA, Schneider PD, Khatri VP, Goodnight JE, Bold RJ. Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy foraxillary staging. Ann Surg Oncol. 2006;13:1450-1456.
64. Motomura K, Egawa C, Komoike Y, et al. Sentinel node biopsy for breast cancer: technical aspects and controversies. Breast Cancer. 2007;14:25-30.
65. Veronesi P, Rodriguez-Fernandez J, Intra M. Controversies in the use of sentinel nodes: microinvasion, post surgery and after preoperative systemic treatment. Breast. 2007;16(suppl 2):S67-S70.
66. Aarsvold JN, Alazraki NP. Update on detection of sentinel lymph nodes in patients with breast cancer. Semin Nucl Med. 2005;35:116-128.
67. Wallace AM, Hoh CK, Ellner SJ, Darrah DD, Schulteis G, Vera DR. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2007;14:913-921.
68. Nieweg OE. Lymphatics of the breast and the rationale for different injection techniques. Ann Surg Oncol. 2001;8(9, suppl):71S-73S.
69. Paganelli G, De Cicco C, Cremonesi M, et al. Optimized sentinel node scintigraphy in breast cancer. Q J Nucl Med. 1998;42:49-53.
70. Mudun A, Sanli Y, Ozmen V, et al. Comparison of different injection sites of radionuclide for sentinel lymph node detection in breast cancer: single institution experience. Clin Nucl Med. 2008;33:262-267.
71. Byrd DR, Dunnwald LK, Mankoff DA, et al. Internal mammary lymph node drainage patterns in patients with breast cancer documented by breast lymphoscintigraphy. Ann Surg Oncol. 2001;8:234-240.
72. Sugg SL, Ferguson DJ, Posner MC, Heimann R. Should internal mammary nodes be sampled in the sentinel lymph node era? Ann Surg Oncol. 2000; 7:188-192.
73. Estourgie SH, Nieweg OE, Olmos RA, Rutgers EJ, Kroon BB. Lymphatic drainage patterns from the breast. Ann Surg. 2004;239:232-237.
74. Farrus B, Vidal-Sicart S, Velasco M, et al. Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan. Int J Radiat Oncol Biol Phys. 2004;60:715-721.
75. Paganelli G, Galimberti V, Trifiro G, et al. Internal mammary node lymphoscintigraphy and biopsy in breast cancer. Q J Nucl Med. 2002;46:138-144.
76. van Rijk MC, Tanis PJ, Nieweg OE, et al. Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer. J Surg Oncol. 2006;94:281-286.
77. Yao MS, Kurland BF, Smith AH, et al. Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer. Ann Surg Oncol. 2007;14:2985-2993.
78. van der Ploeg IM, Kroon BB, Antonini N, Valdes Olmos RA, Rutgers EJ, Nieweg OE. Axillary and extra-axillary lymph node recurrences after a tumornegative sentinel node biopsy for breast cancer using intralesional tracer administration. Ann Surg Oncol. 2008;15:1025-1031.
79. Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E. FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S97-S102.
80. Eubank W, Mankoff D. Current and future uses of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2004;34:224-240.
81. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004;22:277-285.
82. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511-1520.
83. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2005;35:84-99.
84. Eubank WB, Mankoff DA. Current and future uses of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2004;34:224-240.
85. Gil-Rendo A, Zornoza G, Garcia-Velloso MJ, Regueira FM, Beorlegui C, Cervera M. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg. 2006;93:707-712.
86. Kumar R, Zhuang H, Schnall M, et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun. 2006; 27:231-236.
87. Lovrics PJ, Chen V, Coates G, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol. 2004;11:846-853.
88. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol. 2004;30:15-19.
89. Abe H, Schmidt RA, Sennett CA, Shimauchi A, Newstead GM. US-guided core needle biopsy of axillary lymph nodes in patients with breast cancer: why and how to do it. Radiographics. 2007;27(suppl 1):S91-S99.
90. Ciatto S, Brancato B, Risso G, et al. Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging. Breast Cancer Res Treat. 2007;103:85-91.
91. Davis JT, Brill YM, Simmons S, et al. Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasis. Ann Surg Oncol. 2006;13:1545-1552.
92. Memarsadeghi M, Riedl CC, Kaneider A, et al. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus USPIO-enhanced MR imaging. Radiology. 2006;241:367-377.
93. Hathaway PB, Mankoff DA, Maravilla KR, et al. The value of combined FDGPET and magnetic resonance imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology. 1999;210: 807-814.
94. 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat. 2002;75:135-146.
95. Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol. 2004;27:407-410.
96. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outerquadrant tumors: comparison with long-term clinical outcome. J Nucl Med. 2005;46:1455-1459.
97. Jones A, Bernstein V, Davis N, Bryce C, Wilson D, Mankoff D. Pilot feasibility study to assess the utility of PET scanning in the pre-operative evaluation of internal mammary nodes in breast cancer patients presenting with medial hemisphere tumors [abstract]. Clin Positron Imaging. 1999;2:331.
98. Ravaioli A, Pasini G, Polselli A, et al. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat. 2002;72:53-60.
99. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712-720.
100. Shenkier T, Weir L, Levine M, Olivotto I, Whelan T, Reyno L. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ. 2004;170:983-994.
101. Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007;5(suppl 1):S1-S22.
102. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol. 1991;18(4, suppl 5):11-15.
103. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942-2953.
104. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Pastorini F, Buzdar A. A retrospective study of first indicators of breast cancer recurrence. Oncology. 2000;58:185-190.
105. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001;45:53-64.
106. Crippa F, Seregni E, Agresti R, Bombardieri E, Buraggi GL. Bone scintigraphy in breast cancer: a ten-year follow-up study. J Nucl Biol Med. 1993;37:57-61.
107. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-3379.
108. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135-142.
109. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27-37.
110. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381-2389.
111. 18F-fluoride PET/CT. J Nucl Med. 2004;45:272-278.
112. 18F-fluoride: applying new technology to an old tracer. JNuclMed. 2008;49:68-78.
113. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-1804.
114. Hetzel M, ArslandemirC, Konig HH, et al. F-18 NaFPETfordetectionofbone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18:2206-2214.
115. Eubank WB. Diagnosis of recurrent and metastatic disease using F-18 fluorodeoxyglucose-positron emission tomography in breast cancer. Radiol Clin North Am. 2007;45:659-667.
116. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431-435.
117. Mahner S, Schirrmacher S, Brenner W, et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol. 2008;19:1249-1254.
118. Perez EA, Foo ML, Fulmer JT. Management of locally advanced breast cancer. Oncology (Williston Park, N.Y.). 1997;11(9 suppl 9):9-17.
119. Baslaim MM, Bakheet SM, Bakheet R, Ezzat A, El-Foudeh M, Tulbah A. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg. 2003;27:1099-1104.
120. Landheer ML, Steffens MG, Klinkenbijl JH, Westenberg AH, Oyen WJ. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg. 2005;92:1363-1367.
121. 18F-2-fluoro- 2-deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol. 2004;22:1253-1259.
122. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol. 2001;19:3516-3523.